Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

[1]  M. Munsell,et al.  Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Mackay,et al.  Recent and current Phase II clinical trials in endometrial cancer: review of the state of art , 2014, Expert opinion on investigational drugs.

[3]  R. Broaddus,et al.  Personalized therapy in endometrial cancer: Challenges and opportunities , 2012, Cancer biology & therapy.

[4]  H. Mackay,et al.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Oza,et al.  A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Broaddus,et al.  A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.

[7]  B. Shalmon,et al.  AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. , 2010, Gynecologic oncology.

[8]  I. Jonassen,et al.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation , 2009, Proceedings of the National Academy of Sciences.

[9]  D. Matei,et al.  A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer , 2007 .

[10]  Hong Wang,et al.  Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. , 2007, American journal of obstetrics and gynecology.

[11]  Hong Wang,et al.  PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia , 2006, Clinical Cancer Research.

[12]  G. Fleming,et al.  Chemotherapy in endometrial cancer. , 2006, Clinical advances in hematology & oncology : H&O.

[13]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[15]  M. Biswas.  Handbook of Gynaecologic Oncology. , 2004 .

[16]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[17]  Y. Whang,et al.  Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. , 2003, Molecular cancer therapeutics.

[18]  M. Piccart,et al.  Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.